Tukaram Mundhe-led Maharashtra FDA cancels Cipla unit's drug licence over Reactin Plus irregularities
FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an analgesic and antipyretic.
We haven't written up this one. Live Mint has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Maharashtra FDA Cancels Drug Sale Licences Of Cipla Pharma & Life Sciences’ Pune C&F Unit Over Reactin Plus Irregularities freepressjournal.in
- FDA crackdown on Cipla Pharma's Pune unit, license cancelled over 'unauthorised promotional text' hindustantimes.com
- FDA cancels Cipla pharma’s CFA drug sale licence in Pune indianexpress.com
- Maharashtra FDA cancels licence of Cipla's Pune unit economictimes.indiatimes.com
